who achieved objective response assessed by RECIST v1.1/ iRECIST or progression free survival more than 24 weeks. Vactosertib responsive gene signature (VRGS) that showed significantly different expression among previously identified TGF-β responsive gene signature and IFN-γ signature in responders than in non-responders was identified and VRGS score was calculated by a mean value of VRGS filtered-in gene expressions divided by 6 house-keeping gene expressions.

**Results** As of July 1, 2020, of the total evaluable 24 patients, 71% were CMS4 subtype and 33% were with high TMB (≥10 mut/Mb). Clinical benefit rate was 33.3% including 3 PR and 1 iPR patients. No significant associations in response rate were observed with CMS subtypes or TMB status. VRGS score was significantly enriched in responders than in non-responders (P value = 0.006; AUC = 0.836). A preliminary cut-off value of 2.179 resulted in 94% specificity and 75% sensitivity with 85.7% patients correctly classifying as a responder. After treatment of vactosertib plus pembrolizumab, TGF-β-related VRGS was significantly decreased and the extent of decrease was greater in responders, compared to non-responders.

**Ethics Approval** The study was approved by Ethics Board of Asan Medical Center, Yonsei University College of Medicine, Samsung Medical Center, and Seoul National University Bundang Hospital with approval number 2018-1215, 4-2018-0728, SMC 2018-07-146-006, and B-1808/487-003, respectively.

**Conclusions** Development of VRGS as a predictive biomarker for this combination treatment with vactosertib and pembrolizumab is ongoing and its potential clinical utility for patient selection will be explored.

**Trial Registration** NCT03724851

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0332

### 333 TARGETING THE APICAL INTRACELLULAR CHECKPOINT

CISH UNLEASHES T CELL NEOANTIGEN REACTIVITY AND EFFECTOR PROGRAM

1Douglas Palmer, 2Beau Webber, 3Yogin Patel, 4Matthew Johnson, 5Christine Kariya,
2Walker Lahr, 6Maria Parkhurst, 1Jared Garten, 1Todd Prickett, 1Frank Lowery,
1Rigol Kishon, 7Devikula Gurusinghy, 8Zulmarie Franco, 1Suman Vodnal,
7Miechaleen Diers, 6Natalie Wolf, 8Nicholas Slipek, 7David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
4Tom Henley, 4Tilmann Bürckstümmer, 4Oliver Baker, 5Ying Hu,
5Chunhua Yan, 2Natalie Wolf, 2Nicholas Slipek, 2David McKenna,
of this CKM regimen in a non-randomized, single-arm prospective phase II trial.

**Methods** Eligible patients have recurrent/metastatic unresectable CRC with hepatic metastases that are amenable to biopsy. Enrolled patients have prior treatment with or contra-indications to a fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF treatment, and an anti-EGFR targeted therapy (if RAS wt), as well as a PD-1 or PD-L1 targeted drug (if MSI-H/dMMR). Patients receive celecoxib (200 mg orally PO PID), IFNα2b IV (20 million units/m2 IV QD), and rintalimod (200 mg IV QD) on days 1, 2, 3, 8, 9, 10, 15, 16 and 17 in the absence of disease progression or unacceptable toxicity. Response assessment via liver biopsies (pre-treatment and on D20) and CT imaging (RECIST v1.1) on D46. If stable disease/response is demonstrated during repeat CT imaging, patients will continue to follow-up with CT imaging q8 weeks until progression, clinical deterioration, or withdrawal from the study. Primary endpoint assessment compares the change of CD8+ T-cells before treatment, with that seen post-treatment (measured by quantitative RT-PCR and expressed as a ratio of CD8α to a housekeeping gene). Secondary endpoints include objective response rate and safety profile. Subjects are monitored continuously for safety, based on Bayesian analysis. Exploratory endpoints include progression-free survival and overall survival. With a sample size of n=12 evaluable pts, the study design has a 90% power to detect a 0.77 standard deviation increase (pre- to post treatment) at a significance level of 0.1.

**Results** N/A

**Conclusions** N/A

**Trial Registration** ClinicalTrials.gov Identifier: NCT03403634.

**Ethics Approval** The study was approved by Roswell Park Comprehensive Cancer Center’s Institutional Review Board, approval number: MOD00006722/I-52917.

**Consent** N/A

**REFERENCES**


335

**NOVEL COUPLED CAR TM TECHNOLOGY FOR TREATING COLORECTAL CANCER**

**Abstracts**

**Authors**

Song Li, Chengfei Pu, Zhiyuan Cao, Ning Li, Xinyi Yang, Youli Luo, Haiyan Zhao, Hang Yang, Xi Huang, Xiaogang Shen, Xiwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu, Lei Xiao, Hang Yang, Xi Huang, Xiaogang Shen, Xiwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu, Lei Xiao.

**Innovative Cellular Therapeutics, Shanghai, China;** 2Hangzhou University, Hangzhou, China; 3Zhengzhou University, Zhengzhou, China; 4SUN YAT-SEN University, Guangzhou, China; 5Inner Mongolia Medical University, Neimenggu, China

**Background** Chimeric antigen receptor (CAR) T cell therapy has made significant progress in the treatment of blood cancers such as leukemia, lymphoma, and myeloma. However, the therapy faces many challenges in treating solid tumors. These challenges include physical barriers, tumor microenvironment immunosuppression, tumor heterogeneity, target specificity, and limited reactive cell expansion in vivo. Conventional CAR T cell therapy has thus far shown weak cell expansion in solid tumor patients and achieved little or no therapeutic responses. Here, we developed CAR T cells based on a novel CAR® technology to treat solid tumors. In contrast to conventional CAR T cells, CoupledCAR T cells significantly improved the expansion of the CAR T cells in vivo and enhanced the CAR T cells’ migration ability and resistance to immunosuppression by the tumor microenvironment. The enhanced migration ability and resistance allow the CAR T cells to infiltrate to tumor tissue sites and increase anti-tumor activities.

**Methods** We designed a ‘CoupledCAR’ lentivirus vector containing a single-chain variable fragment (scFv) targeting human TSHR. The lentivirus was produced by transfecting HEK-293T cells with ‘CoupledCAR’ lentiviral vectors and viral packaging plasmids. Patient's CD3 T cells were cultured in X-VIVO medium containing 125U/mL IL-2 (II-2), and transduced with ‘CoupledCAR’ lentivirus at certain MOI. Transduction efficiency and was evaluated at 7 to 9 days after ‘CoupledCAR’ lentivirus transduction, and quality controls for fungi, bacteria, mycoplasma, chlamydia, and endotoxin were performed. After infection, serial peripheral blood samples were collected, and the expansion and the cytokine release of CART cells were detected by FACS and QPCR. The evaluation of response level for patients were performed at month 1, month 3, and month 6 by PET/CT.

**Results** Specifically, we engineered CoupledCAR T cells with lentiviral vectors encoding an anti-GCC (guanylate cyclase 2C) CAR molecule. Furthermore, anti-GCC CAR T cells showed anti-tumor activities in vitro and in vivo experiments. To verify the safety and efficacy of CoupledCAR T cells for treating solid tumors, we conducted several clinical trials for different solid tumors, including seven patients with colorectal cancer. These seven patients failed multiple rounds of chemotherapy and radiotherapy. In the clinical trial, the patients were infused with autologous anti-GCC CoupledCAR T cells range from 4.9×10⁶/kg to 2.9×10⁶/kg. All patients using anti-GCC CoupledCAR T cells showed rapid expansion of CoupledCAR T cells and killing of tumor cells. Specifically, we observed that CoupledCAR T cells expanded significantly in the patients and infiltrated tumor tissue sites, demonstrating enhanced anti-tumor activities. PET/CT showed significant tumor shrinkage and SUV max declined, and the ongoing responses were monitored. Patient 3 achieved complete response and the best overall response rate (ORR, include complete remission, complete metabolic response, partial response, and partial metabolic response,) was 71.4% (5/7), complete remission (CR) rate was 14.3% (1/7).

**Conclusions** The clinical data demonstrated that CoupledCAR T cells effectively expanded, infiltrated tumor tissue sites, and kill tumor cells in patients with colorectal cancer. We used immunotherapy to achieve complete remission in patients with advanced colorectal cancer for the first time. We are recruiting more colorectal cancer patients to further test the safety and efficacy of anti-GCC CoupledCAR T cells. Since our CoupledCAR® technology is a platform technology, we are expanding it to treat other solid tumors using different target tumor markers.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0335